US 11,833,151 B2
Pharmaceutical composition including sodium alkyl sulfate
Kenji Kusumoto, Tokushima (JP); and Sadahiro Miyamura, Tokushima (JP)
Assigned to Taiho Pharmaceutical Co., Ltd., Tokyo (JP)
Appl. No. 16/982,377
Filed by TAIHO PHARMACEUTICAL CO., LTD., Tokyo (JP)
PCT Filed Mar. 18, 2019, PCT No. PCT/JP2019/011251
§ 371(c)(1), (2) Date Sep. 18, 2020,
PCT Pub. No. WO2019/181876, PCT Pub. Date Sep. 26, 2019.
Claims priority of application No. 2018-051620 (JP), filed on Mar. 19, 2018.
Prior Publication US 2021/0030755 A1, Feb. 4, 2021
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 9/48 (2006.01); A61K 47/12 (2006.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/0095 (2013.01); A61K 9/14 (2013.01); A61K 9/48 (2013.01); A61K 47/12 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01)] 10 Claims
 
1. A pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one having the following structure, or a pharmaceutically acceptable salt thereof, and sodium lauryl sulfate:

OG Complex Work Unit Chemistry